Sequenom (NASDAQ:SQNM): According to 3 Analysts, The short term target price has been estimated at $ 1.43.The target price could deviate by a maximum of $0.5 from the forecast price. In the near term, the target price could hit a high of $2 and a low of $ 1.
Many analysts have stated their opinion on the company shares. Equity Analysts at the Brokerage Firm, Ladenburg Thalmann, upgrades their rating on the shares of Sequenom (NASDAQ:SQNM). Ladenburg Thalmann has a Neutral rating on the shares. Previously, the analysts had a Sell rating on the shares. The rating by the firm was issued on March 3, 2016. Company shares have received an average consensus rating of Hold for the current week
On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CFO of Sequenom Inc, Beaver Carolyn, had purchased 10,000 shares in a transaction dated on June 9, 2016. The transaction was executed at $1.1 per share with total amount equaling $11,000.
Sequenom (NASDAQ:SQNM) : On Monday heightened volatility was witnessed in Sequenom (NASDAQ:SQNM) which led to swings in the share price. The stock opened for trading at $1.09 and hit $1.15 on the upside , eventually ending the session at $1.11, with a gain of 0.91% or 0.01 points. The heightened volatility saw the trading volume jump to 845,437 shares. The 52-week high of the share price is $3.34 and the company has a market cap of $132 million. The 52-week low of the share price is at $0.9153 .
Sequenom, Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Companys diagnostic services are provided through its wholly owned subsidiary, Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in, and by Sequenom Laboratories, as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of, and reimbursement for its prenatal LDTs, and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories test offerings in the prenatal market include MaterniT21 PLUS LDT, HerediT CF LDT, SensiGene RhD LDT, VisibiliT LDT and Test Send-out Agreements.